Margaret Horn, J.D., serves as the Chief Operating Officer at Revolution Medicines Inc., a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers. With a robust background in the biotechnology and pharmaceutical industries, Margaret brings a wealth of experience and leadership to her role. She holds a Juris Doctor degree, which has equipped her with a strong foundation in legal and business strategies crucial for navigating the complex landscape of drug development and commercialization. Before joining Revolution Medicines, Margaret held several high-profile positions in the biotech sector. She has a proven track record of driving operational excellence and strategic growth, having worked with companies that successfully brought innovative treatments to market. Her expertise spans various aspects of the industry, including business development, corporate strategy, and intellectual property management. At Revolution Medicines, Margaret oversees the company's operational activities, ensuring that the organization's mission to transform cancer treatment is executed efficiently and effectively. Her leadership is instrumental in advancing the company's pipeline of novel RAS(ON) inhibitors, which hold the potential to significantly impact the lives of patients with RAS-driven cancers. Margaret's role as Chief Operating Officer is pivotal in steering Revolution Medicines towards its goal of becoming a leader in precision oncology. Her strategic vision and operational acumen are key drivers in the company's efforts to develop and deliver groundbreaking therapies. Under her guidance, Revolution Medicines continues to build a robust portfolio of drug candidates, fostering collaborations with leading research institutions and leveraging cutting-edge technology to accelerate the development process. Margaret's dedication to advancing cancer research and her commitment to improving patient outcomes make her an invaluable asset to Revolution Medicines and the broader oncology community.